Diffusion-weighted MRI of estrogen receptor-positive, HER2-negative, node-negative breast cancer: association between intratumoral heterogeneity and recurrence risk

Paik S(2004)A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer N Engl J Med 351 2817-2826

Shak S(2006)Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer J Clin Oncol 24 3726-3734

Tang G(2012)Why does Oncotype DX recurrence score reduce adjuvant chemotherapy use? Breast Cancer Res Treat 134 1125-1132

Paik S(2012)Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer J Clin Oncol 30 2218-2226

Tang G(2016)Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American society of clinical oncology clinical practice guideline J Clin Oncol 34 1134-1150

Shak S(2016)Role of patient and disease factors in adjuvant systemic therapy decision making for early-stage, operable breast cancer: American society of clinical oncology endorsement of cancer care Ontario guideline recommendations J Clin Oncol 34 2303-2311

Schneider JG(2016)Prediction of low versus high recurrence scores in estrogen receptor–positive, lymph node–negative invasive breast cancer on the basis of radiologic-pathologic features: comparison with Oncotype DX test recurrence scores Radiology 280 370-378

Khalil DN(2016)MR imaging radiomics signatures for predicting the risk of breast cancer recurrence as given by research versions of MammaPrint, Oncotype DX, and PAM50 gene assays Radiology 281 382-391

Hassett MJ(2018)Apparent diffusion coefficient in estrogen receptor-positive and lymph node–negative invasive breast cancers at 3.0 T DW-MRI: a potential predictor for an Oncotype Dx test recurrence score J Magn Reson Imaging 47 401-409

Silver SM(2018)Diffusion-weighted MRI characteristics associated with prognostic pathological factors and recurrence risk in invasive ER /HER2-breast cancers J Magn Reson Imaging 48 226-236

Paik S(2004)A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer N Engl J Med 351 2817-2826

Shak S(2006)Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer J Clin Oncol 24 3726-3734

Tang G(2012)Why does Oncotype DX recurrence score reduce adjuvant chemotherapy use? Breast Cancer Res Treat 134 1125-1132

Paik S(2012)Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer J Clin Oncol 30 2218-2226

Tang G(2016)Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American society of clinical oncology clinical practice guideline J Clin Oncol 34 1134-1150

Shak S(2016)Role of patient and disease factors in adjuvant systemic therapy decision making for early-stage, operable breast cancer: American society of clinical oncology endorsement of cancer care Ontario guideline recommendations J Clin Oncol 34 2303-2311

Schneider JG(2016)Prediction of low versus high recurrence scores in estrogen receptor–positive, lymph node–negative invasive breast cancer on the basis of radiologic-pathologic features: comparison with Oncotype DX test recurrence scores Radiology 280 370-378

Khalil DN(2016)MR imaging radiomics signatures for predicting the risk of breast cancer recurrence as given by research versions of MammaPrint, Oncotype DX, and PAM50 gene assays Radiology 281 382-391

Hassett MJ(2018)Apparent diffusion coefficient in estrogen receptor-positive and lymph node–negative invasive breast cancers at 3.0 T DW-MRI: a potential predictor for an Oncotype Dx test recurrence score J Magn Reson Imaging 47 401-409

Silver SM(2018)Diffusion-weighted MRI characteristics associated with prognostic pathological factors and recurrence risk in invasive ER /HER2-breast cancers J Magn Reson Imaging 48 226-236